Literature DB >> 3709611

Biliary elimination of indomethacin in man.

B Terhaag, U Hermann.   

Abstract

The biliary elimination of indomethacin 100 mg p.o. has been investigated in patients with a T-tube drain after cholecystectomy, who had normal or abnormal liver function (Group I n = 5, and Group II n = 4, respectively). In plasma, the concentration maximum (Group I 9.5 +/- 1.4 mumol X l-1; Group II 19.4 +/- 3.8 mumol X l-1) and the total clearance (Group I 1.56 +/- 0.28 ml X min-1 X kg-1, Group II 0.5 +/- 0.06 ml X min-1 X kg-1) were significant different in the two groups. The bile:plasma ratio (bpr) in Group I was 1.3 +/- 0.33 and 10.1 +/- 3.2, respectively, for indomethacin (In) and conjugated In. The conjugated fraction of In was 87.5 +/- 1.9% of the total concentration. In Group II the bpr was lower (0.65 +/- 0.1). In is eliminated in bile by diffusion and conjugated In by active secretion. In Group I 0.99 +/- 0.1 mg In and 6.1 +/- 0.7 mg conjugated In and in Group II 2.1 +/- 0.3 mg In (p less than 0.05) were eliminated in bile. No influence of In on the biliary lipids was observed or on the bile acid-independent fraction of bile flow. It is concluded that the total plasma clearance of In was dependent of liver function. Conjugated In undergoes enterohepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709611     DOI: 10.1007/bf00615960

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  The effect of buffered aspirin on plasma indomethacin.

Authors:  J C Garnham; K Raymond; E Shotton; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

3.  A revision of the Schoenheimer-Sperry method for cholesterol determination.

Authors:  W M SPERRY; M WEBB
Journal:  J Biol Chem       Date:  1950-11       Impact factor: 5.157

Review 4.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

5.  The metabolism of indomethacin in man.

Authors:  D E Duggan; A F Hogans; K C Kwan; F G McMahon
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

6.  Effect of halofenate on binding of various drugs to human plasma proteins and on the plasma half-life of antipyrine in monkeys.

Authors:  H B Hucker; S C Stauffer; S E White
Journal:  J Pharm Sci       Date:  1972-09       Impact factor: 3.534

7.  [Pharmacokinetics of indomethacin in patients with kidney lesions].

Authors:  A Traeger; G Stein; M Kunze; J Zaumseil
Journal:  Int J Clin Pharmacol       Date:  1972-08

8.  The renal excretion of indomethacin and its inhibition by probenecid.

Authors:  M D Skeith; P A Simkin; L A Healey
Journal:  Clin Pharmacol Ther       Date:  1968 Jan-Feb       Impact factor: 6.875

9.  Comparative effects of salicylic acid, phenylbutazone, probenecid and other anions on the metabolism, distribution and excretion of indomethacin by rats.

Authors:  D W Yesair; L Remington; M Callahan; C J Kensler
Journal:  Biochem Pharmacol       Date:  1970-05       Impact factor: 5.858

10.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

View more
  3 in total

1.  Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid.

Authors:  R T Foster; F Jamali; A S Russell
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Clearance of indomethacin occurs predominantly by renal glucuronidation.

Authors:  F Moolenaar; S Crancrinus; J Visser; D De Zeeuw; D K Meijer
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

3.  Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3.

Authors:  Regina D Schnegelberger; Brianna Steiert; Philip J Sandoval; Bruno Hagenbuch
Journal:  Front Physiol       Date:  2022-09-08       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.